{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:27:59Z","timestamp":1793039279216,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.trim.2021.101389","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T01:58:09Z","timestamp":1617760689000},"page":"101389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The early impact of preformed angiotensin II type 1 receptor antibodies on graft function in a low immunological risk cohort of kidney transplant recipients"],"prefix":"10.1016","volume":"66","author":[{"given":"Bogdan Marian","family":"Sorohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gener","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Berechet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Obri\u0219c\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ion","family":"M\u0103run\u021belu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorina","family":"Tacu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u0103t\u0103lin","family":"Baston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanel","family":"Sinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2021.101389_bb0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/TP.0b013e31827a19cc","article-title":"Consensus guidelines on the testing and clinical management issues associated with HLA and Non-HLA antibodies in transplantation","volume":"95","author":"Tait","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2021.101389_bb0010","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.3389\/fimmu.2018.03002","article-title":"Development and validation of a multiplex non-HLA antibody assay for the screening of kidney transplant recipients","volume":"9","author":"Kamburova","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trim.2021.101389_bb0015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrneph.2016.88","article-title":"The importance of non-HLA antibodies in transplantation","volume":"12","author":"Zhang","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.trim.2021.101389_bb0020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa035717","article-title":"Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection","author":"Dragun","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2021.101389_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2020.100573","article-title":"Angiotensin II type 1 receptor antibodies in kidney transplantation: An evidence-based comprehensive review","volume":"34","author":"Sorohan","year":"2020","journal-title":"Transplant. Rev."},{"key":"10.1016\/j.trim.2021.101389_bb0030","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/TP.0b013e3181fd97f1","article-title":"Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients","volume":"90","author":"Reinsmoen","year":"2010","journal-title":"Transplantation."},{"key":"10.1016\/j.trim.2021.101389_bb0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2019.01.030","article-title":"Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients","volume":"96","author":"Lefaucheur","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.trim.2021.101389_bb0040","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7903471","article-title":"Not all antibodies are created equal: factors that influence antibody mediated rejection","volume":"2017","author":"Butler","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.trim.2021.101389_bb0045","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/nep.12441","article-title":"C4d-negative antibody-mediated rejection with high anti-angiotensin II type i receptor antibodies in absence of donor-specific antibodies","volume":"20","author":"Fuss","year":"2015","journal-title":"Nephrology."},{"key":"10.1016\/j.trim.2021.101389_bb0050","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1111\/ajt.12397","article-title":"Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss","volume":"13","author":"Giral","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2021.101389_bb0055","series-title":"Pre-Transplant AT1R Antibodies Correlate with Early Allograft Rejection","author":"Gareau","year":"2018"},{"key":"10.1016\/j.trim.2021.101389_bb0060","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1016\/j.transproceed.2018.05.022","article-title":"Preformed angiotensin II Type-1 receptor antibodies are associated with rejection after kidney transplantation: a single-center, cohort study","volume":"50","author":"Kim","year":"2018","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2021.101389_bb0065","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/ajt.12395","article-title":"Higher risk of kidney graft failure in the presence of anti-angiotensin II Type-1 receptor antibodies","volume":"13","author":"Taniguchi","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2021.101389_bb0070","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/TP.0000000000001231","article-title":"Anti-angiotensin II type 1 receptor and anti-endothelial cell antibodies: a cross-sectional analysis of pathological findings in allograft biopsies","volume":"101","author":"Philogene","year":"2017","journal-title":"Transplantation."},{"key":"10.1016\/j.trim.2021.101389_bb0075","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/nep.13239","article-title":"Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies","volume":"24","author":"Malheiro","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.trim.2021.101389_bb0080","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.kint.2017.06.034","article-title":"Angiotensin II type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation","volume":"93","author":"Pearl","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.trim.2021.101389_bb0085","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/tri.13009","article-title":"Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA Luminex era? A retrospective study","volume":"30","author":"Deltombe","year":"2017","journal-title":"Transpl. Int."},{"key":"10.1016\/j.trim.2021.101389_bb0090","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.transproceed.2018.03.020","article-title":"Prevalence of antibody against angiotensin II type 1 receptor (AT1R) among Thai kidney transplant patients","volume":"50","author":"Viboon","year":"2018","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2021.101389_bb0095","first-page":"218","article-title":"Pre-transplant angiotensin II type 1 receptor antibodies: a risk factor for decreased kidney graft function in the early post-transplant period?","volume":"66","author":"Hem\u00e1ndez-M\u00e9ndez","year":"2014","journal-title":"Rev. Investig. Clin."},{"key":"10.1016\/j.trim.2021.101389_bb0100","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/ndt\/gfw204","article-title":"Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies","volume":"31","author":"Cuevas","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.trim.2021.101389_bb0105","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3343\/alm.2018.38.5.450","article-title":"Clinical impact of pre-transplant antibodies against angiotensin II type I receptor and major histocompatibility complex class I-related chain a in kidney transplant patients","volume":"38","author":"Min","year":"2018","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.trim.2021.101389_bb0110","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/tri.12371","article-title":"The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes","volume":"27","author":"Banasik","year":"2014","journal-title":"Transpl. Int."},{"key":"10.1016\/j.trim.2021.101389_bb0115","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.humimm.2018.02.001","article-title":"Pre-transplant screening for non-HLA antibodies: who should be tested?","volume":"79","author":"Philogene","year":"2018","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.trim.2021.101389_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trim.2018.10.003","article-title":"Pretransplant angiotensin II type 1-receptor antibodies point to an increase in renal graft sub-intimal fibrosis in living- donor kidney transplant recipients","volume":"54","author":"Gonz\u00e1lez-Almada","year":"2019","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.trim.2021.101389_bb0125","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1681\/ASN.2016070756","article-title":"The emerging importance of non-HLA autoantibodies in kidney transplant complications","volume":"28","author":"Cardinal","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.trim.2021.101389_bb0130","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.kint.2016.03.019","article-title":"Non-HLA antibodies against endothelial targets bridging Allo- and autoimmunity","volume":"90","author":"Dragun","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.trim.2021.101389_bb0135","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ekir.2018.12.011","article-title":"Cytokine profiles associated with angiotensin II type 1 receptor antibodies","volume":"4","author":"Pearl","year":"2019","journal-title":"Kidney Int. Reports."},{"key":"10.1016\/j.trim.2021.101389_bb0140","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/TP.0000000000000185","article-title":"Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal","volume":"98","author":"Ohe","year":"2014","journal-title":"Transplantation."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327421000290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327421000290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:00:01Z","timestamp":1760810401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327421000290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":28,"alternative-id":["S0966327421000290"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2021.101389","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The early impact of preformed angiotensin II type 1 receptor antibodies on graft function in a low immunological risk cohort of kidney transplant recipients","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2021.101389","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101389"}}